

# Confidence Through Clinical and Real World Experience<sup>1-3</sup>



**#1 Scripted Non-VKA Oral  
Anticoagulant by Cardiologists\***



## Millions of Patients Treated Worldwide Across Multiple Indications<sup>4</sup>

**REFERENCES:** 1. Patel M.R., Mahaffey K.W., Garg J. *et al.* Rivaroxaban versus warfarin in non-valvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883–91. 2. Tamayo S., Peacock W.F., Patel M.R., *et al.* Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban. *Clin Cardiol.* 2015;38(2):63–8. 3. Camm A.J., Amarencio P., Haas S. *et al.* XANTUS: A Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales January 2017.

[S4] Xarelto 15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia [NS2]: 12/8.2/0006; [S2] Botswana: BOT1302296; Zimbabwe: PP10 Reg. 2017/10.2/5363

[S4] Xarelto 20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112; Namibia [NS2]: 12/8.2/0007; [S2] Botswana: BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364

**PHARMACOLOGICAL CLASSIFICATION:** A.8.2 Anticoagulants. **INDICATIONS:** (1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT). For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC). **HCR:** Bayer (Pt) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.

L.ZA.MKT.GM 06.2017.1808

© Bayer June 2017

\*Impact RX Data 2016  
NOAC: Non Vitamin K Oral Anticoagulant

 **Xarelto**<sup>®</sup>  
rivaroxaban